

2010 National Medicinal Chemistry Symposium
University of Minnesota, Minneapolis, MN
June 6-9, 2010

Sunday, June 6

11:00 AM	Registration	Willey Hall
2:00 - 2:15 PM	Opening Remarks: Symposium Chair, Carston R. Wagner; Program Chairs, Yusuf Abul-Hajj, Dave Rotella	Willey Hall
2:15 – 6:00 PM	<p>Oral Session 1: Targeting Neurodegeneration Session Chair: Casey McComas (Merck)</p> <p>Speaker 1: Corey Hopkins, (Vanderbilt University) - Discovery, Characterization, and Antiparkinsonian Effect of a Series of Heterobiarylammides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4</p> <p>Speaker 2: Gabriela Chiosis, (Memorial Sloan Kettering Cancer Center) - Hsp90 inhibitors in neurodegenerative diseases</p> <p>Speaker 3: Mark Layton, (Merck) – Centrally Active NR2B- Subtype Selective NMDA Receptor Antagonists</p> <p>Speaker 4: Sergio Duron, (Afraxis) - Targeting Dendritic Spines in CNS Disorders</p> <p>Speaker 5: Richard Silverman, (Northwestern University) - Selective Neuronal Nitric Oxide Synthase Inhibitors for the Prevention and Treatment of Neurodegenerative Diseases</p>	Willey Hall
6:00 - 7:30 PM	Welcome Reception	Carlson School of Management Atrium

7:30 –
10:00 PM

Oral Session 2: GPR119 as a Target for the Treatment of Type 2 Diabetes

Session Chair: Robert Jones (Arena)

Speaker 1: Nancy Thornberry, (Merck) – New G protein-coupled receptors as potential targets for the treatment of type 2 diabetes

Speaker 2: Andrew Carpenter, (Glaxo Smith Kline) – The Discovery of Potent and Selective GPR119 Agonists for the treatment of type 2 diabetes

Speaker 3: Simon Swain (Prosidion/OSI) – PSN821: A novel oral GPR119 agonist for the treatment of type 2 diabetes producing substantial glucose lowering and weight loss in rodents

Speaker 4: Charles McWherter, (Metabolex) – The Discovery of Novel Agonists of GPR119 receptor for the treatment of type 2 diabetes

Monday, June 7

8:00 AM - 12:00 PM	<p>Oral Session 3: Apoptosis Based Therapies Session Chair: Saul Rosenberg, (Abbott)</p> <p>Speaker 1: Loren Walensky, (Harvard University) - Dissecting and Drugging Apoptotic Pathways with Stapled Peptides of the BCL-2 Family</p> <p>Speaker 2: Milan Bruncko, (Abbott) - Discovery of ABT-263, an Orally Bioavailable Inhibitor of Bcl-2 Family Proteins</p> <p>Speaker 3: Shaomeng Wang, (University of Michigan) - Targeting key apoptosis regulators for new cancer therapeutics</p> <p>Speaker 4: John Flygare, (Genetech) - Inducing Programmed Cell Death in Cancer Cells</p>	Willey Hall
12:15 - 1:50 PM	Lunch	Willey Hall
2:00 PM – 6:00 PM	<p>Oral Session 4: Natural product based-drug design Session Chair: Dale L. Boger, (Scripps Research Institute)</p> <p>Speaker 1: Brian S. J. Blagg, (University of Kansas) - A tale of two tails: Modulation of the Hsp90 N- and C-terminus by small molecules</p> <p>Speaker 2: Brad Moore, (UCSD - Scripps Inst of Oceanography) - Function-oriented biosynthesis of beta-lactone proteasome inhibitors</p> <p>Speaker 3: Gunda I. Georg, (University of Minnesota) - Natural products as leads for anticancer drug discovery</p> <p>Speaker 4: Sam Chackalamannil, (Schering Plough Corporation) - Himbacine-based drug discovery efforts - From antiplatelet agents to antiobesity agents</p> <p>Speaker 5: Dale L. Boger, (Scripps Research Institute) - Vinblastine: Synthetic and Mechanistic Studies</p>	Willey Hall
7:30 – 10:00 PM	Poster Session	Holiday Inn Metrodome

Tuesday, June 8

8:00 AM - 12:00 PM	<p>Oral Session 5: Recent Advances in Drug Metabolism and Pharmacokinetics Session Chairs: Michael Sinz, Kenneth Santone, (BMS Wallingford)</p> <p>Speaker 1: Terry Stouch, (Duquesne University) - A critical appraisal of <i>in silico</i> ADME/Tox: Why models fail: Why models work</p> <p>Speaker 2: Frank Gonzales, (NIH) - PXR/CYP3A4 transgenic mouse model</p> <p>Speaker 3: Gary Skiles, (Amgen) - Perspectives on Reactive Metabolic Intermediates</p> <p>Speaker 4: Joseph Ware, (Genentech) – Transporter Biology in Drug Discovery and Development: Impact of SLCs/ABCs on PK/PD from Mouse to Man</p>	Willey Hall
12:00 - 2:00 PM	Lunch	Willey Hall
2:00 – 6:00	<p>Oral Session 6: Recent Advances in Scale Up and Process Chemistry Session Chair: Robert Larsen (Amgen)</p> <p>Speaker 1: Bruce Lu, (Boehringer-Ingelheim) - Several Practical Regioselective Approaches to Complex 2,3-Disubstituted Indoles</p> <p>Speaker 2: Matt Bio, (Amgen) - The Development of Practical Methods for the Selective Metallation of Heterocycles</p> <p>Speaker 3: Marv Hansen, (Lilly) - Development and Scaleup of Heck, Suzuki-Miyaura and Metalation Reactions</p> <p>Speaker 4: Kirill Lukin, (Abbott) - Process Development for Indazylurea Based TRPV1 Inhibitors</p> <p>Speaker 5: Jacob Janey, (Merck) - The Development of a Biocatalytic Manufacturing Process for Sitagliptin</p> <p>Speaker 6: Jade Nelson, (Pfizer) - Green chemistry to overcome commercialization hurdles</p>	
6:45 PM	Banquet – Nicollet Island	

Wednesday, June 9

8:00 AM - 12:00 PM	ACS Medicinal Chemistry Award Speaker 1: 2010 Division of Medicinal Chemistry Award Speaker 2: TBA Speaker 3: 2010 IUPAC Richter Award Speaker 4: TBA Speaker 5: 2010 OBC Lecture Award	Willey Hall
12:00 - 2:00 PM	Lunch	Willey Hall
2:00 PM – 6:00 PM	Oral Session 7: Fragment Based Drug Discovery Session Chair: David Rees (Astex, UK) Speaker 1: Jack Lin, (Plexxikon) - Scaffold based discovery of indeglitazar, a pan PPAR treatment for metabolic diseases Speaker 2: Chris Murray, (Astex) - Fragment-based Discovery of the HSP90 Inhibitor, AT13387 Speaker 3: Wolfgang Jahnke, (Novartis) - Fragment-based drug discovery: Novel opportunities for well-known targets Speaker 4: Chaohong Sun, (Abbott) – Evolving Trends and Opportunities for Fragment Based Screening Speaker 5: Jon Ellman, (UC Berkeley) – Substrate Activity Screening: A Fragment-Based Method for Inhibitor Discovery	Willey Hall